Inovio Biomedical Corporation’s Advances in Electroporation-Delivered Therapeutic Vaccines Presented at International DNA Vaccine Conference

SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corporation (NYSE Alternext:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, completed multiple scientific presentations at DNA Vaccines 2008, an international conference of leading researchers developing next generation preventive and therapeutic vaccines against diseases with unmet needs. Inovio, in conjunction with its partners, is conducting pioneering studies that are advancing electroporation, a powerful delivery method designed to enhance the potency of DNA-based vaccines against infectious diseases and cancers.